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CURRENT STATUS OF POLIO VACCINATION IN CHILDREN 
The Polio Eradication Initiative for 2019-2023 contains non-epidemic, poliovirus-infected high-risk countries, including 
Ukraine, India, Ethiopia, Uganda and other African countries. The most important tasks facing Ukraine are to help strengthen 
the health and immunization system against polio, stop the spread of all wild polioviruses, all outbreaks of circulating 
polioviruses of the vaccine origin and eliminate the risk of their occurrence in the future.
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В Стратегії по завершенню ліквідації поліомієліту на 2019–2023 рр. зазначені неендемічні країни, що отрима-
ли оцінку «високий ризик» по розповсюдженню поліовірусу, серед яких є Україна, разом з Індією, Ефіопією, Уган-
дою та іншими африканськими країнами. Найважливішими завданнями, поставленими перед Україною, є сприяти 
зміцненню системи охорони здоров'я та імунізації проти поліомієліту, зупинити поширення всіх диких поліовірусів, 
всі спалахи циркулюючого поліовірусу вакцинного походження, усунути ризик появи їх у майбутньому.
Ключові слова: поліомієліт, діти, вакцинація.
В Стратегии по завершению ликвидации полиомиелита на 2019-2023 гг. указаны неэндемичные страны, кото-
рые получили оценку «высокий риск» по распространению полиовируса, среди которых Украина, вместе с Индией, 
Эфиопией, Угандой и другими африканскими странами. Важнейшими задачами, поставленными перед Украиной, 
являются содействие укреплению системы здравоохранения и иммунизации против полиомиелита, остановить 
распространение всех диких полиовирусов, все вспышки циркулирующего полиовируса вакцинного происхожде-
ния, устранить риск появления их в будущем.
Ключевые слова: полиомиелит, дети, вакцинация.
Revalence of the topic. Polio is a viral disease that 
is easily spread in the absence of immunization and 
is still a challenge for modern health care worldwide. 
Polio eradication is a goal of paramount importance, 
as long as polio exists, children in all countries remain 
at risk. Clinically, approximately 1 in 200 children 
(<1% of poliovirus infections among susceptible 
people) develop paralytic polio. Clinical signs of the 
disease without paralysis, characterized by fever for 
several days, malaise, drowsiness, headache, nausea, 
vomiting, constipation or angina occur in 4-8% of peo-
ple infected with poliovirus. 
Asymptomatic infection is the most common clin-
ical form (90-95%) of poliovirus infection in suscep-
tible humans. It is this largest group of infected virus-
es that secrete a fecal virus that is a serious problem 
in the transmission of infection [5].
As part of World Polio Day 2019, an independent 
panel of experts has concluded that wild poliovirus 
type 3 has been eradicated worldwide. The last case of 
wild poliovirus type 3 was detected in northern Nigeria 
in 2012. 
The wild poliovirus type 3 is the second strain of 
polio virus to be eliminated after certification for the 
elimination of wild poliovirus type 2 in 2015. Destruc-
tion of these strains is an important achievement, an in-
centive for the last step the essence of which is the 
elimination of wild poliovirus type 1, which is found 
only in Afghanistan and Pakistan [7]. 
In Ukraine cases of vaccine-associated para-
lytic polio in children were recorded in 2015, 2017 
and 2019. The last confirmed case was recorded in 
an unvaccinated two-year-old child in the Volyn re-
gion. It is known that the coverage of vaccinations 
below 90% loses the main function of vaccination – 
the formation of collective immunity; vaccination 
rates were particularly critical in 2014 (44.7% of chil-
dren vaccinated). 
The result of this trend was the formation of vac-
cine-related variants of poliovirus. Three strains of 
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vaccine-related variants of poliovirus type 2 were de-
tected in 2014, and in 2015, two cases of poliomye-
litis caused by circulating vaccine-related variants of 
poliovirus type 1 were reported. In response to the 
outbreak, 3 rounds of childhood vaccination with oral 
polio vaccine (II round, age group 2 months – 6 years; 
III round – 2 months – 10 years) were conducted in 
October 2015 – February 2016 with coverage levels, 
respectively 64.4%, 71.7% and 80.7%. 
The measures made it possible to improve vacci-
nation coverage (some children under 1 year of age 
received 3 vaccinations: inactivated + oral vaccine), 
which was 90.1%. At the same time, in 10 administra-
tive regions these figures were below 90%. 
Formulation of the problem. Due to the Strategic 
Plan for Polio Eradication and the Final Elimination 
Phase 2013–2018, successful eradication of wild po-
liovirus and circulating poliovirus of vaccine origin 
was carried out. The latter is still causing outbreaks 
in various countries in Africa (Democratic Republic 
of the Congo, Nigeria, Niger, Somalia, Papua New 
Guinea) [3; 6]. As long as poliovirus transmission is 
not interrupted, all countries remain at risk, especially 
those with inadequate health care and immunization. 
The 2019–2023 Initiative identifies three major ob-
stacles to achieving the global elimination of wild po-
liovirus: 1) insecurity and military conflicts, forcing 
families to move massively to refugee camps or inter-
nally displaced persons; 2) weak or vulnerable health 
care systems where families do not have access to ba-
sic health care. 
In these circumstances, large groups of children are 
not immunized or under-immunized, thereby increas-
ing the risk of prolonged circulation and outbreaks; 
3) operational, managerial and resource risks – refers 
to the inability to maintain emergency preparedness, 
function effectively at peak times, lack of human re-
sources, financing, etc. [3]. 
The purpose of the article is actualization of the 
problem of polio vaccination in children; physicians' 
tactics to prevent morbidity in the pediatric population, 
timely detection of wild poliovirus circulation and di-
agnosis of vaccine-related variants of poliovirus.
Basic material. In 2019 Afghanistan and Pakistan 
were the only endemic countries to report 34 cases 
of wild poliovirus transmission due to political con-
flicts, instability combined with poor infrastructures 
and skepticism about health. Polio disability still has a 
profound social character and economic implications. 
Today, approximately 4-5 million people living in 
non-industrial regions suffer from polio and often do 
not have access to medical and rehabilitation programs 
for training, employment and social support. Among 
non-endemic countries, Ukraine has been rated by 
experts as a “high risk” for the spread of poliovirus, 
which determines the need to implement the Polio 
Eradication Initiative for 2019–2023 [3; 15].
The goals of the Polio Eradication Initiative for 
2019–2023 are: I. Elimination (to stop the spread of 
all wild polioviruses, all outbreaks of circulating polio-
virus of vaccine origin, to eliminate the risk of future 
emergence); II. Integration (promote strengthening of 
immunization and health systems, effective surveil-
lance of poliovirus, prepare for, and respond to, out-
breaks and emergencies); III. Certifications (to certify 
the elimination of wild poliovirus, to provide the con-
tent of all polioviruses) [3].
In a collaborative effort, a purposeful approach will 
be taken:
• in endemic countries – undertaking measures to 
prevent the distribution of wild poliovirus in major 
reservoirs;
• in countries where outbreaks are observed, the 
main priority will be to stop circulating vaccine-related 
variants of poliovirus outbreaks and to prevent future 
outbreaks in the future.;
• in non-endemic and unconfirmed outbreaks of 
countries with weak immunization systems, priority 
will be given to improving immunization coverage in 
the highest-level area to minimize the threat of out-
breaks of circulating vaccine-related variants of polio-
virus and to a longer-term objective to enhance sys-
temic immunization and health protection [3; 5; 15]. 
In 2016, the world made the transition from the use 
of trivalent OPV (oral polio vaccine) to bivalent OPV. 
In the near future, the Initiative determines the with-
drawal of bivalent OPV from planned use and the com-
plete cessation of OPV use. The following vaccines are 
currently used in Ukraine to prevent polio:
• Monovalent oral polio vaccine type 1 and 3;
• Bivalent oral polio vaccine;
• Inactivated polio vaccine (IPV).
Vaccination in children is performed at 2 months, 
4 months, 6 months, 18 months, 6 years and 14 years. 
IPV is applicable for I and II vaccinations, with con-
traindications to the introduction of IPV – for all vac-
cinations by age. IPV vaccine can be used for III-VI 
vaccinations both individually and in combination vac-
cines [2]. 
Oral polio vaccine is used for III-VI vaccinations, 
in the absence of contraindications to OPV. For chil-
dren who are HIV-positive or with persons who are 
contraindicated in the introduction of IPV – in a family 
setting or in closed-type institutions, the vaccination is 
performed solely with the IPV vaccine. Vaccine-asso-
ciated paralytic polio is characterized by the develop-
ment of acute fatal paralytic polio cases, as a compli-
cation in children with immunodeficiency associated 
with the use of a live oral attenuated Sebine vaccine. 
The vaccine is a preparation of attenuated strains of 
polio virus type 1 – LSc2ab, type 2 – P712 Ch 2ab and 
type 3 – Leon 12a1b grown on primary kidney cells of 
African green monkeys or on primary culture of kid-
ney cells in African green pastures Vero cell grafting 
cultures [8; 10].
The Sebins strains contained in the OPV originate 
from the DPV. The attenuation renders Sabin's strains 
genetically unstable, which determines their tendency 
to return to strains similar to wild poliovirus that are 
more viable. Some of these "reverberant" strains are 
called "vaccine-related polioviruses. The Polio Erad-
ication Initiative reported 22 cases of vaccine-asso-
ciated paralytic polio in 2017, 33 cases in 2018, and 
24 cases in 2019 worldwide. This complication, ac-
cording to various sources, is observed at a frequen-
cy of 1: 1.5-3 million primary vaccinated and persons 
who have had contact with them. The source of infec-
tion is a vaccinated one that releases the vaccine virus 
through the intestines for several weeks. According to 
WHO recommendations, vaccine-associated paralytic 
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polio can be attributed to the onset of which develops 
not earlier than 4 and not later than 30 days after vacci-
nation, and for contact with vaccinated maximum peri-
od extends to 60 days; excretion of poliomyelitis virus, 
vaccine-related variants of poliovirus and not less than 
4-fold increase in specific antibodies in the blood is 
recorded [3; 4; 12]. 
Unambiguous causes of vaccine-associated par-
alytic polio have not been established. It is generally 
accepted that the immunodeficiency state is a risk fac-
tor for its development in both the recipient and the 
contact of the child. Genetic instability of the vaccine 
strain plays a role in the pathogenesis [12].
The active substance IPV is the antigen of virions 
of wild strains of three immunological types of polio 
virus: 1 type of Mahoney, 2 type of MEF-1, 3 type of 
Saukett grown in the culture of Vero cells or diploid 
human cells. The nominal composition of the vaccine 
is represented by 40 units of type 1, 8 units of type 2 
and 32 units of type 3 D-antigen. D-antigen is the an-
tigen that determines the final concentrations of types 
1, 2 and 3 viruses included in the trivalent IPV. IPV 
production technology is time consuming and requires 
strict monitoring of the inactivation completeness [2].
The recipient's immune responses to IPV and OPV 
vaccination are not the same. IPV causes the forma-
tion of specific antibodies that neutralize the virus in 
the blood and prevent the penetration of the virus into 
the motor neurons of the spinal cord and prevent their 
destruction. IPV is quite safe and effective, it is a spe-
cific component of multicomponent pediatric vaccines, 
including vaccines containing diphtheria, tetanus, 
whooping cough. It should be noted that inactivated 
vaccines have comparatively lower efficacy compared 
to live OPV. IPV vaccine does not protect the tissues of 
the gastrointestinal tract, does not cause local immuni-
ty in the intestine of the vaccinated and thus does not 
restrict the circulation of wild poliovirus in the popula-
tion, because wild poliovirus can cause epidemics [13]. 
Live vaccine creates a longer and more effec-
tive protective immunity, stimulates the production 
of secretory IgA by the intestinal mucosa and limits 
the spread of wild virus, with the replacement of cir-
culating wild poliovirus vaccine strains and natural 
spontaneous immunization of people in contact with 
those who circulate, introduction of IPV. The method 
of administration of the vaccine – oral, simple enough, 
does not require special conditions, equipment and 
apparatus. The vaccination process lasts for several 
weeks and leads to the formation of a sustainable life 
immunity [14]. 
OPV remains an effective tool for responding to 
polio outbreaks even after certification. The complete 
deletion of OPV is planned approximately one year af-
ter the certification of the liquidation of the wild polio-
virus and will be based on the experience of transition 
from trivalent OPV to OPV. In the future, after the ex-
pected certification of global polio eradication in 2022, 
IPV will be the only vaccine used.
In all countries with significant population move-
ments and contacts with poliomyelitis countries, 
surveillance for cases of acute paralysis should be 
strengthened in order to quickly detect any import of 
the virus and facilitate rapid response. In this context, 
high routine immunization is required to minimize the 
effects of virus reintroduction and an active immuni-
zation strategy – in case of outbreaks. Early detection 
and effective response to wild poliovirus is also a key 
factor in maintaining polio-free status. To this end, in-
ternational organizations, governments and stakehold-
ers need to pool global efforts to implement an effec-
tive strategy. In these circumstances, environmental 
surveillance of polioviruses plays a key role in mon-
itoring the import of wild polioviruses and identifying 
new vaccine-related variants of polioviruses. Environ-
mental monitoring includes the control of wastewater 
or other environmental samples for the verification of 
poliovirus. It is known that vaccine-related variants of 
polioviruses and wild poliovirus can remain in waste-
water for two months, depending on environmental 
factors. The experience of many countries, including 
Finland, Egypt, India and Israel, has confirmed that 
environmental oversight can detect vaccine-related 
variants of polioviruses and wild polioviruses before 
the occurrence of acute paralysis [9; 14]. It should be 
noted that in the early stages of the disease, it is dif-
ficult to distinguish polio from other forms of acute 
paralysis. Therefore, to be sure that no case of polio 
will be detected, the observation is aimed at identify-
ing symptoms of acute paralysis, not polio as a disease. 
Qualitative surveillance of acute paralysis is extremely 
important for countries nearing the final phase of polio 
eradication; All cases of this condition in children un-
der 15 years of age and suspected cases of polio in peo-
ple of any age should be reported. A complete clinical, 
epidemiological and virological examination should be 
performed in all cases of acute paralysis [11]. 
It should be noted about the tactics of quarantine 
measures: patients with polio must be isolated, dis-
charged from the hospital not earlier than the 21st day 
after the disease. Due to the fact that the isolation of 
the virus from the intestine sometimes lasts up to 40-60 
days, when transferring the patient to other medical in-
stitutions, it is necessary to give a virological examina-
tion. Persons who have been in contact with sick chil-
dren and adults are subject to medical supervision for 
20 days with daily thermometry. Children and adults 
who have been in contact with a patient with polio, if 
they have fever, catarrhal phenomena, intestinal disor-
ders, are subject to isolation in an infectious hospital 
until the diagnosis is established. For children up to 
7 years, as well as for medical indications and older 
children, unvaccinated or defectively vaccinated polio 
vaccine, at the earliest possible time after contact with 
a patient with poliomyelitis, enter "Human immuno-
globulin normal" once in a dose of 3-6 mg [1]. 
Conclusions. In order to change the status of 
Ukraine as a non-endemic poliovirus high-risk country, 
the routine immunization and immunization of children 
under 10 years of age who have not received the neces-
sary vaccinations by age should be kept high; to carry 
out appropriate epidemiological surveillance of polio, 
cases of acute paralysis and other enterovirus infec-
tions with enhanced virological monitoring of sewage. 
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